Best Practice & Research Clinical Anaesthesiology
Volume 24, Issue 1 , Pages 51-64 , March 2010

Perioperative coagulation management – fresh frozen plasma

  • Daryl J. Kor, MD (Assistant Professor)

      Affiliations

    • Department of Anesthesiology/Division of Critical Care Medicine Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • Multidisciplinary Epidemiology and Translational Research in Intensive Care (M.E.T.R.I.C) Research Group, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 507 255 6051; Fax: +1 507 255 4267.
    • ,
  • James R. Stubbs, MD (Chair)

      Affiliations

    • Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • ,
  • Ognjen Gajic, MD (Associate Professor)

      Affiliations

    • Department of Medicine/Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • Multidisciplinary Epidemiology and Translational Research in Intensive Care (M.E.T.R.I.C) Research Group, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

References 

  1. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion. 2005;45:1413–1425
  2. Wallis JP, Dzik S. Is fresh frozen plasma overtransfused in the United States?. Transfusion. 2004;44:1674–1675
  3. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006;46:1279–1285
  4. Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Current Hematology Reports. 2004;3:324–330
  5. Doyle S, O'Brien P, Murphy K, et al. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagulation & Fibrinolysis. 2003;14:283–287
  6. Wilson K, MacDougall L, Fergusson D, et al. The effectiveness of interventions to reduce physician's levels of inappropriate transfusion: what can be learned from a systematic review of the literature. Transfusion. 2002;42:1224–1229
  7. Holland LL, Foster TM, Marlar RA, Brooks JP. Fresh frozen plasma is ineffective for correcting minimally elevated international normalized ratios. Transfusion. 2005;45:1234–1235
  8. Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm?. Critical Care Medicine. 2006;34:S170–S173
  9. Ng KF, Lai KW, Tsang SF. Value of preoperative coagulation tests: reappraisal of major noncardiac surgery. World Journal of Surgery. 2002;26:515–520
  10. Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Annals of Internal Medicine. 2003;138:W15–W24
  11. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. The Journal of Trauma. 2003;54:1127–1130
  12. MacLeod JB, Lynn M, McKenney MG, et al. Early coagulopathy predicts mortality in trauma. The Journal of Trauma. 2003;55:39–44
  13. Hess JR, Holcomb JB, Hoyt DB. Damage control resuscitation: the need for specific blood products to treat the coagulopathy of trauma. Transfusion. 2006;46:685–686
  14. Hirshberg A, Dugas M, Banez EI, et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. The Journal of Trauma. 2003;54:454–463
  15. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology. 1996;84:732–747
  16. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. British Journal of Haematology. 2004;126:11–28
  17. Guideline for the use of fresh-frozen plasma. Medical Directors Advisory Committee, National Blood Transfusion Council. South African Medical Journal. 1998;88:1344–1347
  18. Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology/The Education Program of the American Society of Hematology. 2007;2007:179–186
  19. Dzik W, Rao A. Why do physicians request fresh frozen plasma?. Transfusion. 2004;44:1393–1394
  20. DeLoughery TG, Liebler JM, Simonds V, Goodnight SH. Invasive line placement in critically ill patients: do hemostatic defects matter?. Transfusion. 1996;36:827–831
  21. Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy–a prospective audit. Intensive Care Medicine. 1999;25:481–485
  22. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Digestive Diseases and Sciences. 1981;26:388–393
  23. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. American Journal of Clinical Pathology. 1990;94:747–753
  24. Chowdhury P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. British Journal of Haematology. 2004;125:69–73
  25. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thrombosis and Haemostasis. 1997;77:477–480
  26. Nifong TP, Light J, Wenk RE. Coagulant stability and sterility of thawed S/D-treated plasma. Transfusion. 2002;42:1581–1584
  27. Kang Y. Thromboelastography in liver transplantation. Seminars in Thrombosis and Hemostasis. 1995;21(Suppl. 4):34–44
  28. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesthesia and Analgesia. 1999;88:312–319
  29. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006;105:198–208
  30. Johansson PI, Stensballe J. Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sanguinis. 2009;96:111–118
  31. Tieu BH, Holcomb JB, Schreiber MA. Coagulopathy: its pathophysiology and treatment in the injured patient. World Journal of Surgery. 2007;31:1055–1064
  32. Plotkin AJ, Wade CE, Jenkins DH, et al. A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. The Journal of Trauma. 2008;64:S64–S68
  33. Stainsby D, MacLennan S, Thomas D, et al. Guidelines on the management of massive blood loss. British Journal of Haematology. 2006;135:634–641
  34. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107:1692–1711
  35. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2001;119:22S–38S
  36. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S–198S
  37. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition–2005 update. British Journal of Haematology. 2006;132:277–285
  38. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. The Medical Journal of Australia. 2004;181:492–497
  39. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. Journal of Thrombosis and Haemostasis. 2008;6:622–631
  40. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thrombosis Research. 2005;115:455–459
  41. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. British Journal of Neurosurgery. 2000;14:458–461
  42. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470
  43. Patel T. Surgery in the patient with liver disease. Mayo Clinic Proceedings. 1999;74:593–599
  44. Friedman LS. The risk of surgery in patients with liver disease. Hepatology. 1999;29:1617–1623
  45. Ailawadi G, Lapar DJ, Swenson BR, et al. Model for end-stage liver disease predicts mortality for tricuspid valve surgery. The Annals of Thoracic Surgery. 2009;87:1460–1467discussion 1467–1468
  46. Garrison RN, Cryer HM, Howard DA, Polk HC. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Annals of Surgery. 1984;199:648–655
  47. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Seminars in Liver Disease. 2002;22:83–96
  48. Everson GT. A hepatologist's perspective on the management of coagulation disorders before liver transplantation. Liver Transplantation and Surgery. 1997;3:646–652
  49. Diaz LK, Teruya J. Liver biopsy. The New England Journal of Medicine. 2001;344:2030
  50. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion. 2003;67:138–145
  51. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. Journal of Hepatology. 2007;46:727–733
  52. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006;44:1039–1046
  53. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005;41:553–558
  54. Massicotte L, Beaulieu D, Thibeault L, et al. Coagulation defects do not predict blood product requirements during liver transplantation. Transplantation. 2008;85:956–962
  55. Massicotte L, Sassine MP, Lenis S, Roy A. Transfusion predictors in liver transplant. Anesthesia and Analgesia. 2004;98:1245–1251table of contents
  56. Stewart RM, Myers JG, Dent DL, et al. Seven hundred fifty-three consecutive deaths in a level I trauma center: the argument for injury prevention. The Journal of Trauma. 2003;54:66–70discussion 70–61
  57. Cosgriff N, Moore EE, Sauaia A, et al. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. The Journal of Trauma. 1997;42:857–861discussion 861–852
  58. Eddy VA, Morris JA, Cullinane DC. Hypothermia, coagulopathy, and acidosis. The Surgical Clinics of North America. 2000;80:845–854
  59. Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. The Journal of Trauma. 2006;60:S91–S96
  60. Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfusion Medicine Reviews. 2003;17:223–231
  61. Kauvar DS, Holcomb JB, Norris GC, Hess JR. Fresh whole blood transfusion: a controversial military practice. The Journal of Trauma. 2006;61:181–184
  62. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. The Journal of Trauma. 2007;63:805–813
  63. Spinella PC, Perkins JG, Grathwohl KW, et al. Effect of plasma and red blood cell transfusions on survival in patients with combat related traumatic injuries. The Journal of Trauma. 2008;64:S69–S77discussion S77–68
  64. Duchesne JC, Hunt JP, Wahl G, et al. Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years?. The Journal of Trauma. 2008;65:272–276discussion 276–278
  65. Jansen JO, Thomas R, Loudon MA, Brooks A. Damage control resuscitation for patients with major trauma. BMJ. 2009;338:b1778
  66. Teixeira PG, Inaba K, Shulman I, et al. Impact of plasma transfusion in massively transfused trauma patients. The Journal of Trauma. 2009;66:693–697
  67. Sperry JL, Ochoa JB, Gunn SR, et al. An FFP: PRBC transfusion ratio >/= 1:1.5 is associated with a lower risk of mortality after massive transfusion. The Journal of Trauma. 2008;65:986–993
  68. Johansson PI, Hansen MB, Sorensen H. Transfusion practice in massively bleeding patients: time for a change?. Vox Sanguinis. 2005;89:92–96
  69. Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. The Journal of Trauma. 2006;60:S51–S58
  70. Johansson PI, Stensballe J, Rosenberg I, et al. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion. 2007;47:593–598
  71. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Annals of Surgery. 2008;248:447–458
  72. Snyder CW, Weinberg JA, McGwin G, et al. The relationship of blood product ratio to mortality: survival benefit or survival bias?. The Journal of Trauma. 2009;66:358–362discussion 362–354
  73. Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. British Journal of Haematology. 1987;67:365–368
  74. Murray DJ, Olson J, Strauss R, Tinker JH. Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology. 1988;69:839–845
  75. Aggeler PM. Physiological basis for transfusion therapy in hemorrhagic disorders: a critical review. Transfusion. 1961;1:71–86
  76. Guidelines on oral anticoagulation: third edition. British Journal of Haematology. 1998;101:374–387
  77. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. American Journal of Clinical Pathology. 2006;126:133–139
  78. Holland L, Sarode R. Should plasma be transfused prophylactically before invasive procedures?. Current Opinion in Hematology. 2006;13:447–451
  79. Youssef WI, Salazar F, Dasarathy S, et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. The American Journal of Gastroenterology. 2003;98:1391–1394
  80. Mannucci PM, Franchi F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. 1976;2:542–545
  81. Reutter JC, Sanders KF, Brecher ME, et al. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis. 2001;16:134–138
  82. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. The Journal of Trauma. 2006;60:S46–S50
  83. Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions–guidelines for healthcare providers. Resuscitation. 2008;77:157–169
  84. Lieberman P. Biphasic anaphylactic reactions. Annals of Allergy, Asthma & Immunology. 2005;95:217–226quiz 226, 258
  85. Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2007;62:830–837
  86. Popovsky MA, Audet AM, Andrzejewski C. Transfusion-associated circulatory overload in orthopedic surgery patients: a multi-institutional study. Immunohematology. 1996;12:87–89
  87. Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. The Journal of Bone and Joint Surgery. American Volume. 1999;81:2–10
  88. Rana R, Fernandez-Perez ER, Khan H, et al. Transfusion related pulmonary edema in the intensive care unit. Chest. 2005;128(Suppl):130S
  89. Rana R, Mendez JL, Rickman OB, et al. Transfusion related acute lung injury in medical intensive care unit: a four months pilot prospective study. Proceedings of the American Thoracic Society. 2005;B51S
  90. Popovsky MA. Transfusion and the lung: circulatory overload and acute lung injury. Vox Sanguinis. 2004;87(Suppl. 2):62–65
  91. Zhou L, Giacherio D, Cooling L, Davenport RD. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion. 2005;45:1056–1063
  92. Aravinthan A, Sen S, Marcus N. Transfusion-related acute lung injury: a rare and life-threatening complication of a common procedure. Clinical Medicine. 2009;9:87–89
  93. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44:1774–1789
  94. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Critical Care Medicine. 2005;33:721–726
  95. Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfusion Medicine Reviews. 2004;18:184–188
  96. Goldman M, Webert KE, Arnold DM, et al. Proceedings of a consensus conference: towards an understanding of TRALI. Transfusion Medicine Reviews. 2005;19:2–31
  97. Fatalities reported to the FDA following blood collection and transfusion. In: Proceedings of the Annual Summary for Fiscal Year 2008.
  98. Wallis JP. Transfusion-related acute lung injury (TRALI)–under-diagnosed and under-reported. British Journal of Anaesthesia. 2003;90:573–576
  99. Triulzi DJ. Transfusion-related acute lung injury: an update. Hematology/The Education Program of the American Society of Hematology. 2006;1:497–501
  100. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Critical Care Medicine. 2007;35:1645–1648
  101. Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest. 2007;131:1308–1314
  102. Holness L. Analysis of fatalities reported to the FDA. Consensus Conference: Towards an Understanding of TRALI 2004;Toronto, Ontario, Canada.
  103. Palfi M, Berg S, Ernerudh J, Berlin G. A randomized controlled trial of transfusion-related acute lung injury: is plasma from multiparous blood donors dangerous?. Transfusion. 2001;41:317–322
  104. Serious Hazards of Transfusion Steering Group . Serious hazards of transfusion 2003 annual report. Available from: http://wwwshotukorg/SHOT%20Report%202003pdf
  105. Serious Hazards of Transfusion Steering Group . Serious hazards of transfusion 2004 annual report. Available from: http://wwwshotukorg/SHOTREPORT2004pdf
  106. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. American Journal of Respiratory and Critical Care Medicine. 2007;176:886–891
  107. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003–2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion. 2007;47:599–607
  108. Wright SE, Snowden CP, Athey SC, et al. Acute lung injury after ruptured abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma. Critical Care Medicine. 2008;36:1796–1802
  109. AABB Association Bulletin 06–07 Transfusion-related acute lung injury. Available from: http://wwwaabborg2006;
  110. Code of Federal Regulations, 21 CFR 640.34(a) and (b).
  111. Cardigan R, Lawrie AS, Mackie IJ, Williamson LM. The quality of fresh-frozen plasma produced from whole blood stored at 4 degrees C overnight. Transfusion. 2005;45:1342–1348
  112. O'Neill EM, Rowley J, Hansson-Wicher M, et al. Effect of 24-hour whole-blood storage on plasma clotting factors. Transfusion. 1999;39:488–491
  113. Smith JF, Ness PM, Moroff G, Luban NL. Retention of coagulation factors in plasma frozen after extended holding at 1–6 degrees C. Vox Sanguinis. 2000;78:28–30
  114. Vassallo R. Issues to consider when converting frozen plasma to thawed plasma. AABB News. 2007;9:16–17
  115. Standard 5.7.5.12. Standards for blood banks and transfusion services. 25th ed.. Bethesda: AABB; 2008;35
  116. Downes KA, Wilson E, Yomtovian R, Sarode R. Serial measurement of clotting factors in thawed plasma stored for 5 days. Transfusion. 2001;41:570
  117. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology. 2008;109:918–926
  118. Lorenz R, Kienast J, Otto U, et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. European Journal of Gastroenterology & Hepatology. 2003;15:15–20
  119. Stuklis RG, O'Shaughnessy DF, Ohri SK. Novel approach to bleeding in patients undergoing cardiac surgery with liver dysfunction. European Journal of Cardio-thoracic Surgery. 2001;19:219–220
  120. Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. British Journal of Anaesthesia. 2009;102:345–354
  121. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation annotation. British Journal of Haematology. 2001;114:271–280
  122. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. British Journal of Haematology. 2002;116:619–624
  123. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thrombosis Research. 2006;118:313–320
  124. Goodnough LT, Shander AS. Recombinant factor VIIa: safety and efficacy. Current Opinion in Hematology. 2007;14:504–509
  125. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Critical Care Medicine. 2005;33:883–890
  126. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. British Journal of Anaesthesia. 2005;95:596–602
  127. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201–205
  128. Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001;71:402–405
  129. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion. 2005;45:26–34
  130. Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplantation. 2005;11:973–979
  131. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005;102:269–275
  132. Shao YF, Yang JM, Chau GY, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. American Journal of Surgery. 2006;191:245–249
  133. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879
  134. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. The Journal of Trauma. 2005;59:8–15discussion 15–18
  135. Novo Nordisk stock exchange announcement. Available from: http://www.novonordisk.com/press/sea/sea.asp[accessed June 19, 2009]
  136. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. The New England Journal of Medicine. 2005;352:777–785
  137. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123–1130
  138. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293–298
  139. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Annals of Allergy, Asthma & Immunology. 2007;98:383–388

PII: S1521-6896(09)00071-8

doi: 10.1016/j.bpa.2009.09.007

Best Practice & Research Clinical Anaesthesiology
Volume 24, Issue 1 , Pages 51-64 , March 2010

Article Tools

* Image Usage & Resolution